Bellicum Pharmaceuticals (BLCM) has released an update.
On January 24, 2024, a special meeting was held by a company to approve the sale of certain assets to The University of Texas M. D. Anderson Cancer Center and to address the potential liquidation and dissolution of the company contingent on that sale. The assets in question pertain to various research and development programs in cell therapy safety and enhancement. However, due to the lack of a quorum, the meeting was adjourned to allow more time for stockholder voting on the proposed asset sale and dissolution, with a future date to be announced for the reconvened meeting.
For further insights into BLCM stock, check out TipRanks’ Stock Analysis page.
